| abstract |
Compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods for their synthesis, and methods for their therapeutic and/or prophylactic use are provided. Such compounds can be used by themselves, or together with incretin peptides such as GLP-1(7-36), GLP-1(9-36) and oxyntomodulin, or with peptide-based such as exenatide and Liraglutide) therapy together as a modulator or potentiator of the GLP‑1 receptor and has the following general structure (wherein, represents one or both of the R-form and the S-form of the compound): wherein A, B, C, R 1 , R 2 , R 3 , R 4 , R 5 , n, p and q are as defined herein. |